GysanDBMillentrupSAlbusCet al.Substantial improvement of primary cardiovascular prevention by a systematic score-based multimodal approach: a randomized trial – The PreFord Study. Eur J Prev Cardiol2017; 24: 1544–1554.
2.
VestergaardNSogaardPTorp-PedersenCet al.Relationship between treatment of erectile dysfunction and future risk of cardiovascular disease: a nationwide cohort study. Eur J Prev Cardiol2017; 24: 1498–1505.
3.
McLaughlinTHarnettJBurhaniSet al.Evaluation of erectile dysfunction therapy in patients previously nonadherent to long-term medications: a retrospective analysis of prescription claims. Am J Ther2005; 12: 605–611.
4.
FantinFComellatoGRossiAPet al.Relationship between neck circumference, insulin resistance and arterial stiffness in overweight and obese subjects. Eur J Prev Cardiol2017; 24: 1532–1540.
5.
NielsenSGuoZJohnsonCMet al.Splanchnic lipolysis in human obesity. J Clin Invest2004; 113: 1582–1588.
6.
RuddoxVSandvenIMunkhaugenJet al.Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis of studies published between 2006 and 2016. Eur J Prev Cardiol2017; 24: 1555–1566.
7.
Taleb BendiabNSMeziane-TaniAOuabdesselamSet al.Factors associated with global longitudinal strain decline in hypertensive patients with normal left ejection fraction. Eur J Prev Cardiol2017; 24: 1463–1472.
8.
ShahRVMurthyVLAbbasiSAet al.Weight loss and progressive left ventricular remodelling: the Multi-Ethnic Study of Atherosclerosis (MESA). Eur J Prev Cardiol2015; 22: 1408–1418.
9.
PiepoliMFHoesAWAgewallSet al.2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Prev Cardiol2016; 23: NP1–NP96.
10.
ErikssonMCarlbergBPennlertJet al.Time trends and socioeconomic differences in blood pressure levels. The Northern Sweden MONICA Study 1994–2014. Eur J Prev Cardiol2017; 24: 1473–1481.
11.
Penaloza-RamosMCJowettSBartonPet al.Cost-effectiveness analysis of different systolic blood pressure targets for people with a history of stroke or transient ischaemic attack: economic analysis of the PAST-BP study. Eur J Prev Cardiol2016; 23: 1590–1598.
12.
BerkelmansGFNVisserenFLJJaspersNEMet al.SPRINT trial. It’s not just the blood pressure!. Eur J Prev Cardiol2017; 24: 1482–1484.
13.
WattsGFGiddingSWierzbickiASet al.Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Eur J Prev Cardiol2015; 22: 849–854.
14.
SbranaFDal PinoBBigazziFet al.Statin intolerance in heterozygous familial hypercholesterolemia with cardiovascular disease: after PCSK-9 antibodies what else?Eur J Prev Cardiol2017; 24: 1528–1531.
15.
ChristensenRHvon ScholtenBJHansenCSet al.Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary excretion rate. Eur J Prev Cardiol2017; 24: 1517–1524.
16.
KotsevaKWoodDDe BacquerDet al.EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol2016; 23: 2007–2018.
17.
KhanAAChungMJNovakEet al.The long-term risk of smoking in diabetic patients with stable ischemic heart disease treated with intensive medical therapy and lifestyle modification. Eur J Prev Cardiol2017; 24: 1506–1514.
18.
RauchBDavosCHDohertyPet al.The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: a systematic review and meta-analysis of randomized and non-randomized studies – The Cardiac Rehabilitation Outcome Study (CROS). Eur J Prev Cardiol2016; 23: 1914–1939.
19.
PardaensSWillemsAMClaysEet al.The impact of drop-out in cardiac rehabilitation on outcome among coronary artery disease patients. Eur J Prev Cardiol2017; 24: 1490–1497.
